Biolase continues restructuring sales team, names new executives in Q3: 7 things to know

In the third quarter, Biolase made a series of leadership changes and reworked the structuring of its sales team.

Here are seven things to know:

1. The company has made strides in restructuring its sales team, inclusive of offering more training and development for field-based sales leaders.

2. Biolase named Jonathan Lord, MD, as board chairman.

3. The company appointed Richard Lanman, MD, to the board of directors, effective Nov. 1.

4. John Beaver is the company's new senior vice president and CFO, effective Oct. 1.

5. The company's third quarter financial results include:
•    Net revenue of $10.8 million
•    Operating expenses of $7.6 million
•    Net losses of $4.6 million

6. For the first nine months of 2017, Biolase reported net revenue of $34.3 million and operating expenses of $24.8 million.

7. Biolase had net losses of $13 million for the first nine months of this year.

More articles on dental:
11 states with highest Medicaid FFS reimbursement rates for adult dental care services
Number of medical malpractice payment reports for dentists across 50 states: Which state ranks as No. 1 at 3.3k?
8 metropolitan areas with highest dentist employment

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

New From Becker's Dental Review

Aspen Dental, Henry Schein & more: 7 dental companies making headlines

Read Now